Moleculin Biotech Receives FDA Guidance for Phase 3 Trial on Annamycin-Cytarabine Combination
Moleculin Biotech, Inc. (NASDAQ: MBRX) recently announced that it has received crucial feedback and guidance from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) amendment. This development has allowed for a reduction in the size of the Phase 3 pivotal trial protocol evaluating the Annamycin in combination with Cytarabine for […]
